Copyright
©The Author(s) 2023.
World J Clin Cases. May 6, 2023; 11(13): 2890-2902
Published online May 6, 2023. doi: 10.12998/wjcc.v11.i13.2890
Published online May 6, 2023. doi: 10.12998/wjcc.v11.i13.2890
Study name | Year | Drug molecule | Mean weight reduction (95%CI/SD) | Mean HbA1c reduction in % (95%CI/SD) | Ref. |
Exenatide-113 Clinical Study | 2004 | Exenatide 10 mcg twice daily | -1.6 kg (SD +/-0.3) | -0.86 (SD +/- 0.11) | [10] |
EXSCEL study | 2017 | Exenatide (ER) Once weekly | -1.27 kg (-1.40 to -1.13) | -0.53 (-0.57 to -0.50) | [11] |
LEAD 3 (Mono) Trial | 2009 | Liraglutide 1.2 mg daily | -1.6 kg (-2.43 to -0.88) | -1.21 (-1.35 to -1.06) | [12] |
SUSTAIN 7 Trial | 2018 | Dulaglutide 1.5 mg weekly | -3.0 kg (SD: 0.27) | -1.4 (SD: -0.06) | [12] |
SUSTAIN 7 Trial | 2018 | Semaglutide 1 mg weekly | -6.5 kg (SD: -0.28) | -1.8 (SD: -0.06) | [12] |
- Citation: Khor XY, Pappachan JM, Jeeyavudeen MS. Individualized diabetes care: Lessons from the real-world experience. World J Clin Cases 2023; 11(13): 2890-2902
- URL: https://www.wjgnet.com/2307-8960/full/v11/i13/2890.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i13.2890